Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

WAYNE, N.J. and EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.  NExUS evaluated Nexavar versus placebo in combination with two chemotherapeutic agents, gemcitabine and cisplatin.  A positive secondary endpoint of progression-free survival (PFS) was observed in the trial.  The safety and tolerability of the treatment triplet was as expected and did not show any new or unexpected toxicities.  Data from this study are expected to be presented at an upcoming scientific meeting.

Nexavar is currently marketed worldwide for the treatment of hepatocellular carcinoma (HCC), or liver cancer, and advanced renal cell carcinoma (RCC), or kidney cancer.

Enrollment in NExUS commenced in February 2007. In 2008, based on the results seen in a previous Nexavar first-line NSCLC Phase 3 trial, the NExUS study protocol was amended to stop enrolling and treating squamous cell carcinoma patients.  Of the squamous cell patients who were enrolled in the NExUS trial before the amendment, a higher mortality was observed.  This finding was consistent with what was seen in the previous trial.  

Bayer and Onyx will further review the findings of this analysis to det
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ... today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") ... 2014. The terms of the acquisition were not disclosed. ... ("DME") company providing a wide range of sleep, mobility, and ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... May 11 The U.S. Food and Drug Administration recently approved ... 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in ... , , ... , , ...
... HAYWARD, Calif. and Buffalo Grove, Ill. , May 11 ... Alma Lasers, Inc. today announced that they have reached an agreement resolving lawsuits ... , , ... in the U.S. District Court in Delaware by Alma Lasers ...
Cached Medicine Technology:FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 2FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System 3Solta Medical and Alma Lasers Resolve Patent Lawsuits 2Solta Medical and Alma Lasers Resolve Patent Lawsuits 3
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... Will Educate Families And Increase Landlord ... ... Women and The Sherwin-Williams Company are pleased to announce "NOT,IN OUR ... arising from poor maintenance and neglect and to encourage property,owners and ...
... Sept. 10 Maxim Health Systems today,announced it will ... 2007. Maxim will provide flu shots nationwide through more,than ... http://www.FindAFluShot.com, helps users find a convenient location for,vaccination ... on the site to,obtain times and locations for clinics. ...
... DIEGO, Sept. 10 Conflict is an issue that ... to have little preparation on,how to communicate effectively to ... school bullies. These rivalries can be harmful,to children, whether ... violent behavior, and anger management issues. It is ...
... A lesser known,antibiotic-resistant bacteria is a growing ... are seeing the potentially deadly staph,infection known as ... South Texas was one of the first ... since become a hot bed for the infection. ...
... Breathe Act, MINNEAPOLIS, Sept. 10 Today ... to educate and excite Minnesotans about the,Freedom to ... into effect,on October 1. The new law will ... private clubs. Called Fresh Air, the,multimedia campaign is ...
... ... the Advancement of Science, PHILADELPHIA and LONDON, Sept. 10 ... ; TSX: TOC) and,leading provider of information solutions to the ... Laureates,-- researchers likely to be in contention for Nobel honors ...
Cached Medicine News:Health News:National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 3Health News:Tips for Parents: Teaching Children to Resolve Conflicts 2Health News:South Texas Doctors Report More Severe Cases of Community Staph 'Super Bug' Hospitalizing Children 2Health News:Fresh Air Campaign to Showcase Minnesotans' Love of Smoke-Free Air 2Health News:Thomson Scientific Predicts Nobel Laureates 2Health News:Thomson Scientific Predicts Nobel Laureates 3Health News:Thomson Scientific Predicts Nobel Laureates 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: